Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have received a consensus rating of "Buy" from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $21.00.

Several analysts have weighed in on the stock. Guggenheim started coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $20.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. William Blair raised Zevra Therapeutics to a "strong-buy" rating in a report on Friday, August 30th. Finally, Roth Mkm increased their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th.

Institutional Trading of Zevra Therapeutics

Several large investors have recently added to or reduced their stakes in ZVRA. Virtu Financial LLC acquired a new stake in Zevra Therapeutics in the third quarter worth about $127,000. Barclays PLC raised its position in shares of Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company's stock worth $399,000 after buying an additional 42,926 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock worth $7,246,000 after acquiring an additional 129,600 shares during the period. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics in the third quarter valued at approximately $94,000. Finally, State Street Corp increased its stake in shares of Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company's stock valued at $5,363,000 after acquiring an additional 52,966 shares during the period. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 2.0 %

Shares of ZVRA stock traded down $0.17 during trading hours on Friday, hitting $8.39. 330,491 shares of the company were exchanged, compared to its average volume of 546,249. The stock has a market capitalization of $447.86 million, a price-to-earnings ratio of -4.26 and a beta of 1.97. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The business's 50-day simple moving average is $8.74 and its two-hundred day simple moving average is $7.33. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the business earned ($0.40) EPS. Sell-side analysts predict that Zevra Therapeutics will post -1.96 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.